ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
化工社オープンプロジェクト:[email protected]AIアクセス:llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.7.8
  1. ホーム
  2. /化合物

(1S,4S,4aR,5R,8R,8aS)-1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-1,4:5,8-dimethanonaphthalene

HCID 61103
ノート反応
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

標準SMILES
ClC1=C(Cl)[C@@]2(Cl)[C@H]3[C@H]([C@H]4C=C[C@H]3C4)[C@@]1(Cl)C2(Cl)Cl
InChIKey
QBYJBZPUGVGKQQ-VFBQXPTHSA-N
分子式
C12H8Cl6
平均分子量
364.9 g/mol
単同位体質量
361.875716

概要

Aldrin can cause cancer according to an independent committee of scientific and health experts.

名称と識別子

優先名称
(1S,4S,4aR,5R,8R,8aS)-1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-1,4:5,8-dimethanonaphthalene
IUPAC
(1S,2S,3R,6R,7R,8S)-1,8,9,10,11,11-hexachlorotetracyclo[6.2.1.13,6.02,7]dodeca-4,9-diene

名称と別名

DTXSID10947432(1s,4s,4ar,5r,8r,8as)-1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-1,4:5,8-dimethanonaphthaleneRefChem:1049532DTXCID201375690C07552SCHEMBL28042673

データベース識別子

PubChem CID
61103
DTXSID
DTXSID10947432

物性

構造計算による物性

XLogP
4.5
極性表面積
0 Ų
水素結合供与体数
0
水素結合受容体数
0
回転可能結合数
0
重原子数
18
形式電荷
0
複雑度
481

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

安全と保護具

Minimum Risk LevelAcute Oral: 0.002 mg/kg/day (L134) Chronic Oral: 0.00003 mg/kg/day (L134)

毒性情報

TreatmentTreatment is symptomatic, aimed at controlling convulsions, coma, and respiratory depression. If ingested, gastric lavage may be performed, followed by administering activated charcoal powder. (L145)
Health Effects · 1 件

Aldrin is a neurotoxin and works by overstimulating the central nervous system. Ingestion of large amounts of aldrin causes convulsions and death. However, chronic exposure to lower amounts of aldrin also has adverse affects because it is oxidized to dieldrin, which accumulates in the body. Dieldrin is known to damage the nervous system, liver, and immune system. (L87)

Exposure RoutesOral (L87) ; inhalation (L87) ; dermal (L87)
Toxicity Summary · 1 件

Aldrin antagonizes the action of the neurotransmitter gamma-aminobutyric acid (GABA) acting at the GABA-A receptors, effectively blocking the GABA-induced uptake of chloride ions. Aldrin also inhibits Na+ K+ ATPase and Ca2+ and Mg2+ ATPase which are essential for the transport of calcium across membranes. This results in the accumulation of intracellular free calcium ions, which promotes release of neurotransmitters from storage vesicles, the subsequent depolarization of adjacent neurons, and the propagation of stimuli throughout the CNS. This results in hyperexcitation and generalized seizures. (T10, L87)

Signs and SymptomsExposure to aldrin results in headaches, dizziness, irritability, nausea and vomiting, cardiac arrhythmias, muscular weakness, uncontrolled muscle movements, hyperexcitability, seizures and coma. (L87)
Carcinogen Classification3, not classifiable as to its carcinogenicity to humans. (L135)

化学と産業

薬理情報

Metabolism/Metabolites · 1 件

Aldrin is absorbed throught the gastrointestinal tract, lungs and skin. Following absorption, aldrin is redistributed primarily to fat via the lymphatic system. Once in the body, aldrin is readily converted to dieldrin, primarily in the liver by mixed-function oxidases of the cytochrome P-450 system, and to a lesser extent in the lung and skin. Aldrin may also be epoxidized to dieldrin by a prostaglandin synthetase-mediated pathway inextrahepatic tissues. Dieldrin is metabolized by liver microsomal monooxygenases and epoxide hydratases. Its metabolites, of which the primary one is 9-hydroxydieldrin, are excreted in the faeces. (L87)

用途と製造

UsesAldrin is used as an insecticide. (L144)

関連反応

0 件
反応記録を作成

現在のフィルター条件では反応記録がありません。

化合物ノート

読み込み中…

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
Toxicity DataLD50: 39 mg/kg (Oral, Rat) (T18) LD50: 98 mg/kg (Dermal, Rat) (T18) LD50: 150 mg/kg (Intraperitoneal, Rat) (T17) LD50: 21 mg/kg (Intravenous, Mouse) (T17)